loading page

Biological risk based on preoperative serum CA19-9 and histology grade predicts prognosis in patients with pancreatic cancer
  • +4
  • Shaofei Chang,
  • Yaohua Liu,
  • Yuexiang Liang,
  • Quan Man,
  • Haorui Li,
  • Yu Guo,
  • Tiansuo Zhao
Shaofei Chang
Tianjin Medical University
Author Profile
Yaohua Liu
Shanxi Medical University
Author Profile
Yuexiang Liang
Tianjin Medical University
Author Profile
Quan Man
Tianjin Medical University
Author Profile
Haorui Li
Tianjin Medical University
Author Profile
Yu Guo
Tianjin Medical University
Author Profile
Tiansuo Zhao
Tianjin Medical University

Corresponding Author:[email protected]

Author Profile

Abstract

Background: Preoperative serum CA19-9 and histology grade could reflect the biological characteristics of pancreatic ductal adenocarcinoma (PDAC). This study aims to explore the combined effect of preoperative CA19-9 and histology grade on the prognosis of patients with PDAC. Methods: A total of 612 patients with PDAC undergoing curative pancreatectomy were retrospectively enrolled. A biological risk model was established based on preoperative CA19-9 and histology grade. Prognostic significance of the biological risk was evaluated. Results: 360 (58.8%) patients had preoperative CA19-9>112 U/ml and 348 (56.9%) patients had high histology grade. Biological risk based on preoperative CA19-9 and histology grade was independently associated with survival of PDAC patients. The biological risk was incorporated into the eighth edition of the TNM staging system and a modified TNM (mTNM) staging system was developed. The ROC curves showed that the area under curve(AUC) of the mTNM staging system was significantly greater than that of the TNM staging system. Conclusion: Biological risk based on preoperative CA19-9 and histology grade was an independent prognostic factors for patients with PDAC. Incorporating the biological risk into the TNM staging system could improve the the accuracy of the TNM staging system in predicting prognosis of PDAC.
15 Jun 2023Submitted to Cancer Reports
15 Jun 2023Submission Checks Completed
15 Jun 2023Assigned to Editor
15 Jun 2023Review(s) Completed, Editorial Evaluation Pending
15 Jun 2023Reviewer(s) Assigned
10 Jul 2023Editorial Decision: Revise Major
05 Aug 20231st Revision Received
07 Aug 2023Submission Checks Completed
07 Aug 2023Assigned to Editor
07 Aug 2023Review(s) Completed, Editorial Evaluation Pending
08 Aug 2023Reviewer(s) Assigned
24 Aug 2023Editorial Decision: Revise Minor
29 Aug 20232nd Revision Received
01 Sep 2023Submission Checks Completed
01 Sep 2023Assigned to Editor
01 Sep 2023Review(s) Completed, Editorial Evaluation Pending
14 Sep 2023Editorial Decision: Accept